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Original Article
The Results of Evisceration with Primary Porous Implant 
Placement in Patients with Endophthalmitis
Young-Gun Park, Ji-Sun Paik, Suk-Woo Yang
Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, 
The Catholic University of Korea School of Medicine, Seoul, Korea
Purpose: To assess the results and long-term prognosis of evisceration with primary porous implant placement in 
patients with endophthalmitis.
Methods: A retrospective study was conducted to review the files of 27 patients (29 eyes) with endophthalmitis who 
underwent evisceration with primary porous implant placement from January 1997 to December 2007 at St. 
Mary’s Hospital and Kangnam St. Mary’s Hospital. The mean follow-up period was 12.24 months (range, 3 to 89 
months) and the mean age of the patients was 63.6 years (range, 33 to 89 years).
Results: During the surgical procedure, primary implant placement was successfully completed, and any post-
operative infection or inflammation rapidly resolved in all 27 patients (29 eyes). One of two porous implant materi-
als was used. Hydroxyapatite was inserted in 14 eyes and Medpor was inserted in 15 eyes. Delayed implant ex-
posure was noted in 1 eye, which was treated by inserting a hydroxyapatite implant 18 months after the first 
surgery. This was well treated by a preserved scleral graft. Implant infection was noted in 1 other eye at 20 days 
after the first surgery. All other minor complications healed without sequelae.
Conclusions: Evisceration with primary porous implant placement as the treatment for recalcitrant endophthalmitis 
resulted in rapid resolution of any infection and inflammation. Implant exposure and infection occurred in only 2 
eyes, and these problems were well treated without long-term sequelae. Therefore, evisceration with primary po-
rous implant placement is a treatment option for patients with endophthalmitis. 
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Endophthalmitis can be caused by many events, includ-
ing intraocular surgery, trauma, corneal ulcer, or systemic 
infection. The traditional approach for the management of 
fulminant endophthalmitis that is refractory to other forms 
of treatment is to perform an evisceration or enucleation 
[1,2].  
With the development of antibiotics, evisceration in the 
setting of endophthalmitis is preferred to enucleation be-
cause evisceration is thought to have less risk of post-
operative meningitis or encephalitis. But in most cases, the 
use of orbital implantation has been restricted to a silicone 
ball or polymethyl methacrylate (PMMA) [3].
Porous orbital implants are now commonly used after en-
cucleation and evisceration and as secondary orbital 
implants. The advantage of porous orbital implants is that 
the resultant fibrous ingrowth may reduce the risk of ex-
trusion, and small exposures may heal spontaneously. 
Porous orbital implants also enhance cosmesis and improve 
the motility of the artificial eye, and so the use of porous or-
bital implants has increased [4,5].
Yet, there exists the belief that primary implantation of 
porous implants at the time of evisceration in patients with 
endophthalmitis carries a high risk of complications such as 
exposure, extrusion and dissemination of infection. On the 
basis of this premise, primary porous orbital implantation 
has not been advocated in the setting of refractory 
endophthalmitis. Available implant materials have been 
limited to a silicone ball or PMMA, or patients undergo a 
two-stage operation (first-stage evisceration followed by 
delayed second-stage porous orbital implant insertion).
Tawfik and Budin [6] recently reported no complications Korean J Ophthalmol Vol.24, No.5, 2010
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Table 1. Patient characteristics: cause, implant type, size, culture results, and complications of 29 patients who underwent










1 67/M OD Ulcer No growth H 20   5 None
2 58/F OS Trauma No growth M 20   5 None
3 89/F OD Ulcer No growth M 20   8 None
4 75/F OD Trabe No growth M 18   5 None
5 34/M OS Trauma No growth M 20   8 None
6 47/F OS Trauma No growth M 16   3 None
7 47/F OD Trauma No growth M 16   6 None
8 73/F OD Cataract Escherichia coli M2 0 1 6 N o n e
9 83/F OD Ulcer Klebsiella  pneumoniae M1 8 2 8 N o n e
10 67/F OS Ulcer No growth M 18 18 Implant exposure
11 62/M OS Trauma No growth M 20   9 None
12 70/M OD Trauma Aspergillus flavus M2 0  9 N o n e
13 61/F OS Ahmed valve No growth M 18   5 None
14 61/F OD Cataract No growth H 18   4 None
15 33/M OD Trauma No growth H 20   8 None
16 46/F OS Trauma No growth H 20 13 Conjunctival  dehiscence
17 77/M OS Trauma No growth  H 18   1 None
18 77/F OS Ulcer No growth  M 18   5 None
19 85/F OD Ulcer No growth  M 20   8 None
20 68/M OD Endogenous Streptococcus pneumoniae H2 0  9 N o n e
21 46/F OS Trauma No growth  H 20   8 None
22 73/F OD Vitrectomy No growth H 18   7 None
23 49/M OD Trauma Klebsiella pneumoniae H2 0 8 9 N o n e
24 51/M OD Trauma Klebsiella pneumoniae H 20 29 Infection
25 83/F OS Ulcer No growth H 16   8 None
26 46/M OD Trauma No growth H 20   4 None
27 79/F OS Trauma No growth H 20   6 None
28 70/M OS Endogenous No growth H 20   9 None
29 67/M OD Vitrectomy No growth H 20   7 None
Trabe = trabeculectomy; H = hydroxyapatite; M = Medpor.
when 16 porous orbital implants were used in a total of 66 
patients with endophthalmitis. However, the general utility 
of primary porous implant placement at the time of eviscer-
ation is not well established with regard to possible 
infection. The purpose of this study is to evaluate the results 
of this treatment approach for patients with endophthalmitis. 
Materials and Methods
We reviewed the records of 27 patients (29 eyes) who un-
derwent evisceration with primary porous implant place-
ment by a single surgeon for the management of fulminant 
endophthalmitis between 1997 and 2007 at St. Mary’s 
Hospital and Kangnam St. Mary’s Hospital. The majority of 
these patients were aggressively treated with topical, intra-
cameral and/or intravenous antibiotics before evisceration. 
The patients were generally referred when these measures 
failed to control the infection or the structural integrity of 
the blind eye was severely compromised. All patients had 
signs of persistent ocular inflammation. The charts were re-
viewed for predisposing conditions such as age, the date of 
surgery, gender, prior ocular surgery and the surgical proce-
dure and technique. The type and size of the orbital implants 
were also evaluated. In order to assess the organisms that 
caused the endophthalmitis, the intraocular contents re-
moved during surgery were cultured and the sensitivity of 
the bacteria was tested. Biopsy was also performed to ascer-
tain that a malignant neoplasm was not misconstrued as 
endophthalmitis. Finally, the complications that remained, 
such as infection, inflammation, and exposure or extrusion 
of the porous orbital implant material, were evaluated. The 
‘fit’ of the postoperative prosthesis and the patients’ sat-
isfaction were examined.
Surgical technique
For the eviscerations, a 360° peritomy was performed and 
the sclera was incised just posterior to the surgical limbus. 
An evisceration spoon or periosteal elevator was used to 
separate the uvea from the sclera and to deliver the intra-YG Park, et al. Primary Porous Implantation in Endophthalmitis
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Table 2. Distribution of age and gender
Age (yr) Male Female Total
 0-30  0  0 0
31-50  4  4 8
51-70  7  4 11
71-89  1  9 10
Total 12 17 29
Table 3. Follow-up periods
Follow-up (mon) Total
0–9 2 2
1 0–1 9 4
2 0–2 9 2
3 0–8 9  1
Total 29
Table 4. Culture results of the eye contents
Organisms  Number
Streptococcus pneumoniae  1
Klebsiella pneumoniae  3
Escherichia coli  1
Other (Aspergillus flavum) 1
No growth 23
Total 29
Table 5. Types and sizes of the porous implants used
Implant size (mm) Hydroxyapatite Medpor Total
16 2 2 4
18 2 5 7
20 11 7 18
Total 15 14 29
Table 6. Post-operative complications and their management
Complications No. of cases (%) Treatment Result
Implant exposure 1 (3.5) Scleral graft (13×12 mm) Well repaired
Conjunctival wound dehiscence 1 (3.5) Conservative care Self-healed
Infection of implant 1 (3.5) Removal of porous implant and replacement with silicone ball  Well controlled 
ocular contents. The interior of the scleral shell was scraped 
or cleaned with gauze to remove all visible remnants of 
uveal tissue. In addition, the surgeon routinely used dehy-
drated (absolute) alcohol to remove residual pigment from 
the scleral wall. Anterior relaxing incisions that measured 
approximately 1 cm were made medially and laterally, 
avoiding the medial and lateral rectus muscles. The posteri-
or sclera was also opened around the optic nerve with a 
combination of sharp and blunt dissection. A porous im-
plant that was infiltrated with antibiotic solution was placed 
in the scleral shell, and this was closed in layers with 5-0 
Vicryl sutures. The overlying Tenon’s capsule and con-
junctiva were closed with 6-0 Vicryl suture. A conformer 
and antibiotic ointment were placed within the fornices and 
the procedure was completed.
Results
The medical records of 27 patients (29 eyes) who under-
went evisceration for endophthalmitis with primary porous 
orbital implant placement at St. Mary’s Hospital and 
Kangnam St. Mary’s Hospital were reviewed (Table 1). The 
ages of the patients ranged from 33 to 89 years (mean age, 
63.6 years). There were 17 females and 12 males (Table 2). 
The mean follow-up period was 12.2 months (range, 3 to 89 
months) (Table 3). 
The culture and sensitivity results were available for 29 
patients. The result was no growth in 23 patients, presum-
ably because of the heavy administration of topical and sys-
temic antibiotics prior to surgery. The culture results were 
positive for Streptococcus pneumoniae in 1 patient, Klebsiella 
pneumoniae in 3 patients and Escherichia coli in 1 patient; 
1 culture grew Aspergillus flavum (Table 4). Histopathologic 
evaluation of the intraocular contents was routinely per-
formed for all patients to rule out any incidental finding of 
malignancy, but none was found. 
Fifteen patients received hydroxyapatite implants, and 14 
patients received Medpor
  implants. Among the patients 
who received hydroxyapatite implants, 2 patients received a 
16 mm implant, 2 patients received an 18 mm implant and 
11 patients received a 20 mm implant. Among those who re-
ceived Medpor implants, 2 patients received 16 mm im-
plants and 5 patients received 18 mm implants. The remain-
ing 7 patients received a 20 mm Medpor implant (Table 5).
 After surgery, implant exposure (13×12 mm) was noted 
in 1 patient at 16 months after surgery and this was success-
fully treated with a preserved scleral graft. Suppurative dis-
charge and odor were noted in 1 patient at 20 days after sur-
gery; the abscess was evacuated and the orbital implant was 
changed to a silicone ball. Other complications included 1 
patient in whom marked conjunctival wound dehiscence 
developed during the early postoperative period (20 days). 
This conjunctival defect took months to re-epithelialize un-
der conservative treatment without implant exposure (Table 6).
All the patients were successfully fitted with an ocular 
prosthesis.
Discussion
In the case of recalcitrant endophthalmitis, evisceration 
may be preferable to enucleation to reduce the potential risk 
of intracerebral infectious spread. Evisceration offers many Korean J Ophthalmol Vol.24, No.5, 2010
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advantages over enucleation, including improved post-
operative fornices and implant motility, easier prosthetic fit-
ting and generally improved cosmesis [1,6,7]. Evisceration 
is considered a safe procedure that has therefore recently 
gained more interest and acceptance. 
Another important consideration after eye removal is se-
lection of an orbital implant. Polyethylene is a high-density, 
straight-chain hydrocarbon that is formed by polymer-
ization of ethylene molecules under high temperature and 
pressure. The porous polyethylene orbital implant is manu-
factured by heating and compaction of polyethylene gran-
ules into spherical shapes of different sizes. This material is 
nontoxic, nonallergenic and highly biocompatible. It is not 
brittle, thus allowing suturing of muscles directly to it and 
more importantly, its porous matrix facilitates ingrowth of 
the host’s fibrovascular tissue [8]. This should reduce the 
risk of migration, exposure and extrusion and minimize the 
risk of infection. If signs of infection are found, systemic 
antibiotics work well to treat them
 [9-11]. The porous orbi-
tal implants are relatively more lightweight than a silicone 
ball or PMMA, which theoretically reduces the pressure 
over the lower eyelid. Furthermore, if it is needed, this orbi-
tal implant is ideally suited for a second operation using peg 
system or motility coupling post, and it helps to increase 
movement of the prosthetic eyeball by keeping the extra-
ocular muscles [5,6].
Primary insertion of porous implants after evisceration 
has been limited to noninfectious situations. This is because 
a belief exists that primary implantation of porous material 
at the time of evisceration in the setting of endophthalmitis 
carries a high risk of complications such as exposure, ex-
trusion and dissemination of infection [11,12]. As a result, 
the use of orbital implantation has been restricted to a sili-
cone ball or PMMA, or patients undergo a two-stage oper-
ation
  (first-stage evisceration followed by delayed sec-
ond-stage porous orbital implant insertion) [3,13].
In recent studies, Dresner and Karesh [7] reported 1 porous 
polyethylene exposure in a series of 11 patients with Pseudo- 
monas aeruginosa endophthalmitis. Tawfik and Budin [6]
 
also reported no complications, including exposure or in-
fection, when 16 porous orbital implants were used for a total 
66 patients with endophthalmitis. That study shows the pos-
sibility of successful primary porous orbital implant place-
ment in patients with endophthalmitis. 
Our results are compatible with those of Dresner and 
Karesh [7] and Tawfik and Budin [6]. The patients that 
needed to undergo surgery again due to complications were 
limited to 2 eyes (6.9%) among 29 eyes that had eviscera-
tion with primary porous implant placement because of 
endophthalmitis. According to Remullar et al. [4], porous 
orbital implants can be easily exposed when the blood ves-
sels of the implants are not well formed. Without this fi-
brovascular ingrowth at the anterior surface of the implant, 
the roughened surface of the implant may lead to con-
junctival wound dehiscence and attrition to the sclera and 
progressive anterior implant migration and eventual ex-
posure, and this can be accompanied by other complications 
such as infection [9,11].
However, primary porous orbital implant placement with 
evisceration in patients with endophthalmitis is preferred 
because it can reduce the patients’ concerns about needing 
additional surgery and it can increase their satisfaction as 
related to cosmesis. With standard evisceration, it is usually 
not possible to place anything larger than an 18 mm sphere. 
Several modifications to the procedure have been reported 
to enable the placement of larger implants within the scleral 
cavity. Most of these techniques include cutting the sclera 
anteroposteriorly with or without separating the optic nerve 
from the scleral flaps. With this technique, we were able to 
acquire enough cavity space to insert the implant. After 
identifying the size of the cavity, we used 20 mm implants 
in our patients. Possibly, these incisions created a route for 
fibrovascular ingrowth in the porous orbital implant and 
thus prevented implant exposure. 
With regard to bacterial culture from the surgical site, cul-
tures from 23 out of 29 eyes did not grow organisms. The 
reason for this is that the patients with endophthalmitis re-
ceived systemic antibiotics and topical antibiotics before 
surgery. There was no case in which a patient who received 
artificial eyes complained about orbital deformities or 
asked for reconstructive surgery after the initial surgery. 
Primary porous implant placement after evisceration can 
be possible if the surgery is performed selectively. Once an 
infectious scleritis spreads in the adjacent sclera, medical 
management alone is usually not effective. It is believed 
that antibiotics do not adequately penetrate the nearly avas-
cular sclera. Thus, evisceration with primary porous orbital 
implants may be the procedure of choice in the setting of se-
vere endophthalmitis that is not accompanied by scleral ab-
scesses and perforations. 
Moreover, none of our cases showed gross purulent dis-
charge within the orbit. Our approach in the setting of re-
fractory endophthalmitis is to perform an evisceration with 
a primary porous orbital implant and thoroughly examine 
the socket for signs of gross contiguous infection. If there is 
no evidence of gross purulent orbital infection, then we in-
sert a primary porous orbital implant at that time. 
In summary, we present a case series of porous orbital im-
plants after evisceration, along with the follow-up results. 
Based on these results, primary porous implantation after 
evisceration in patients with endophthalmitis can be tolerated 
and has a relatively low incidence rate of complications. 
The authors note that the results of this study are only a 
reflection of the particular surgical methods used and 
should not be used in all cases. In other words, the 1 patient 
who needed a reoperation due to persistence of infection 
should not be overlooked. It means the method should be 
properly chosen according to the patient’s condition. It is 
possible only when a relatively healthy sclera is available 
because the compromised structural integrity of the sclera YG Park, et al. Primary Porous Implantation in Endophthalmitis
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may not adequately support an orbital implant.
The results of this study present evisceration with pri-
mary porous implants as a new possibility for treatment of 
patients with endophthalmitis. The proper selection of pa-
tients remains mainly a matter of the surgeon’s decision, 
and more research is required to compare outcomes. In con-
clusion, the results of our study suggest that evisceration 
with primary porous orbital implant placement for endoph-
thalmitis is an available treatment strategy that carries an 
acceptably low risk of complications. 
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